NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Allogene Therapeutics, Inc. (ALLO) Stock Analysis

Allogene Therapeutics, Inc. (ALLO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ALLO

$1.33

$0.00 (0.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ALLO with… →

ALLO Key Statistics

As of Oct 21, 2026
Trading
Open
$1.33
Previous Close
$1.33
Day's Range
1.31–1.37
52-Week Range
1.04–4.46
Volume
4.73M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.56
Valuation
Market Cap
$459.50M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
99.03
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.66
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$190.89M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
345.49M
1-Year Return
+5.56%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
5.70M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ALLO closed at $1.33, +5.56% over 1 year.

Allogene Therapeutics, Inc. (ALLO) has a market capitalization of $459.50M.

In fiscal 2025, ALLO reported revenue of $0.00.

ALLO Stock Return by Calendar Year

Allogene Therapeutics, Inc. (ALLO) return since Oct 2018: what $10,000 became

1 year
$10,000 $10,556
+5.56%
5 years
$10,000 $834
−91.66%
Since Oct 2018
$10,000 $532
−94.68%

If you had invested $10,000 in Allogene Therapeutics, Inc. (ALLO) at the close on October 11, 2018, the earliest close on record here, it would have been worth $532 at the close on October 21, 2026: −94.68% in total, −30.61% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−2.92%
2025−35.68%
2024−33.64%
2023−48.97%
2022−57.84%
2021−40.89%
2020−2.85%
2019−3.53%
2018 (partial year)+7.72%

As of October 21, 2026.

ALLO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$190.89M—
2024$22.00K−$257.59M−1,170,863.6%
2023$95.00K−$327.27M−344,489.5%
2022$156.00K−$340.41M−218,214.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$206.93M−$190.89M—
2024$22.00K—−$257.48M−$257.59M−1,170,863.6%
2023$95.00K—−$314.49M−$327.27M−344,489.5%
2022$156.00K—−$335.54M−$340.41M−218,214.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ALLO Valuation vs Biotechnology Median

Median of 608 stocks
MetricALLOBiotechnology medianvs median
P/S ratio99.0313.307.4x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Allogene Therapeutics, Inc. (ALLO) is capitalised at $459.50M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 150.

The 52-week range on file runs from $1.04 to $4.46. The most recent close on file for ALLO is $1.33, dated October 21, 2026. The close was unchanged from the previous session. The latest close sits 27.88% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. That is −100.00% against the prior fiscal year, when revenue was $22.00K. The same year closed with a net loss of $190.89M. Trailing earnings per share are −0.66.

Across the 4 fiscal years on file, revenue moves from $156.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 99.03. On price-to-sales that is 7.4 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is +5.56%. Across 5 years the annualized return works out at −39.15%. Beta against the wider market is reported at 0.56. Annualized volatility over the trailing 8 years is 77.11%.

Growth & Income

The record shows no dividend for ALLO.

2026 is still running; the total return is −2.92% year to date. The strongest complete calendar year on file is 2020 at −2.85%; the weakest is 2022 at −57.84%. Of the 7 complete calendar years on file, 0 finished higher.

Peer Comparison

Allogene Therapeutics, Inc. (ALLO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Allogene Therapeutics, Inc. ALLO $459.50M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Allogene Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Visit website →